Vimarsana
Biggest News Aggregation in the World

Page 44 - Ipid Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ipid Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ipid Management Today - Breaking & Trending Today

Index Identifies Subclinical Heart Failure Risk in Type 2 Diabetes - Vimarsana News

Index Identifies Subclinical Heart Failure Risk in Type 2 Diabetes

The triglyceride-glucose index correlated with subclinical heart failure with preserved ejection fraction in asymptomatic patients with type 2 diabetes.

Red Blood Cells Made to Deliver Antibiotics to Bacteria - Vimarsana News

Red Blood Cells Made to Deliver Antibiotics to Bacteria

A “smart blood” platform delivered antibiotics to E coli without harming normal cells.

Olpasiran Provides Large Sustained Cut in Lp(a): OCEAN(a)-DOSE - Vimarsana News

Olpasiran Provides Large Sustained Cut in Lp(a): OCEAN(a)-DOSE

The small interfering RNA product showed reductions of more than 95% in levels of Lp(a) at doses of 75 mg or more when given every 12 weeks in a new phase 2 study.

Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial - Vimarsana News

Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial

In the phase 3 PROMINENT trial, pemafibrate improved multiple lipid fractions in patients with type 2 diabetes, without any impact on cardiovascular events.

New Trial Suggests CV Benefit With EPA: RESPECT-EPA - Vimarsana News

New Trial Suggests CV Benefit With EPA: RESPECT-EPA

Although the open-label trial has many limitations, it could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose eicosapentaenoic acid.